Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-Paclitaxel and Bevacizumab Followed by Bevacizumab and Erlotinib in Triple Negative Advanced Breast Cancer
NCT00733408Phase 2Completed
- Sponsor
- University of Washington
- Start
- Apr 2008
- Primary completion
- Jul 2017
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of paclitaxel, bevacizumab, erlotinib in triple negative breast cancer (TNBC), sponsored by University of Washington. Started Apr 2008; status: completed.
02
Drugs
paclitaxelbevacizumaberlotinib
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT00733408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00733408.